Overview

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this clinical research study is to determine whether dapagliflozin can improve (decrease) blood glucose values in patients with Type 2 diabetes who have never been treated with medication or have been taking medication for less than 24 weeks since their original diabetes diagnosis. The safety of this treatment will also be studied.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Bristol-Myers Squibb

Treatments:

Dapagliflozin
Metformin